Highly efficient T cell manufacturing process with reduced handling steps using CellGenix® reagents in the G-Rex® system
Discover how enhanced T cell expansion along with the generation of an early differentiated phenotype can be achieved.
The manufacturing process of T cell products such as CAR-T cells needs to yield a sufficient number of cells with defined properties in a reasonable time frame. Defined reagents and procedures are important for a fully commercializable manufacturing process, suitable for T-cell production at scales required for a clinically available therapy, whilst a reasonable time frame is important for cell viability, patient access and cost-effectiveness.
In this application note, discover how enhanced T cell expansion along with the generation of an early differentiated phenotype can be achieved using the G-Rex® system with CellGenix serum-free reagents, such as CellGenix® T Cell Medium (CellGenix TCM) supplemented with CellGenix® IL-7 and IL-15.
Using serum-free reagents in your bioprocessing removes potential risk or variability introduced when using human serum, yielding a product with a low proportion of PD-1+ cells. The G-Rex® system reduces handling steps for more efficient production, eliminating the need to change media and refeed cytokines over an 11-day culture.